Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion

摘要

The identification of driver mutations in epidermal growth factor receptor, anaplastic lymphoma kinase, the and genes and subsequent successful clinical development of kinase inhibitors not only significantly improves clinical outcomes but also facilitates the discovery of other novel driver mutations in non-small cell lung cancer. These driver mutations can be categorized into mutations in or near the kinase domain, gene amplification or fusion. In this review, V600E, and exon 20 mutation, –4, , , , , , and gene aberration and their therapeutics will be discussed.